Wolfgang Miesbach: Weight-Bearing Lunge Test for Ankle Assessment in Haemophilia?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn about a recent article by Firat Tan et al, published in Haemophilia, adding:
”Weight-Bearing Lunge Test for ankle assessment in haemophilia?
In a new open-access paper in Haemophilia, Tan et al. systematically evaluate the weight-bearing lunge test (WBLT) as a functional, ankle‑specific outcome in young people with haemophilia who have only limited joint damage.
This is a simple test where the patient stands facing a wall and lunges forward, trying to touch the knee to the wall while keeping the heel on the ground.
The distance from the toes to the wall (or the angle of the tibia) reflects how much dorsiflexion the ankle can achieve in a weight‑bearing position – similar to everyday activities such as walking or stair climbing.
This study is the first to rigorously validate WBLT in haemophilia. It shows excellent test–retest reliability and demonstrates that WBLT results correlate with haemophilia‑specific joint health scores (HJHS), ankle‑focused ultrasound findings (HEAD‑US), and smartphone‑based tibial inclination measurements in children and young adults on prophylaxis with low overall joint scores.
By focusing on patients with minimal structural damage, the authors demonstrate that WBLT can uncover subtle, clinically relevant functional ankle deficits that conventional joint scoring alone may miss.
This positions WBLT as a practical, low‑cost addition to routine ankle monitoring and rehabilitation outcome assessment in haemophilia care.
Congratulations to the authors Firat Tan, Selin Aytac, Adalet Elcin Yildiz, Prof, Edir, Hande G.”
Title: Weight-Bearing Lunge Test in Young Patients With Haemophilia and Limited Joint Damage: Reliability and Functional Associations for Ankle Assessment
Authors: Firat Tan, Selin Aytac, Adalet Elcin Yildiz, Hande Guney Deniz
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 30, 2026, 03:06Salvatore Brugaletta: Is Twelve Months of DAPT Still Too Long After ACS?
-
Jun 30, 2026, 02:55Edward Lee Carter: How A Landmark Stewardship Shift Reduced Unnecessary Antiplatelet Use Across VISN 8
-
Jun 30, 2026, 02:43Nicolas Gendron: More than a Research Fellowship – Leaving the Wagner Lab
-
Jun 30, 2026, 02:29Wolfgang Miesbach: Can We ‘Pre‑Tame’ the Immune System to Unlock Better AAV8 FVIII Expression?
-
Jun 30, 2026, 02:21Mohammad Khalil: Evaluating DAPT Duration after Percutaneous Coronary Intervention
-
Jun 30, 2026, 02:11Rishdha Roshad: Activated Clotting Time – Adult vs Pediatric
-
Jun 30, 2026, 02:02Julia Castillo González: Role of Cortistatin During the Acute and Subacute Phases of Ischemic Stroke
-
Jun 29, 2026, 23:26Sandy Middleton: The 2026 Stroke Clinical Care Standard Has Arrived with Nursing Leadership at Its Core
-
Jun 29, 2026, 22:14To Continue or Interrupt DOAC Therapy? The Evidence Remains Unclear – RPTH Journal